Table III.

Comparison of asthmatic children with and without palivizumab exposure

Demographic factors (n = 191)	Palivizumab unexposed (n = 90)	Palivizumab exposed (n = 101)	P value
GA (wk), mean ± SD	27.23 ± 2.46	26.89 ± 2.20	.314
BBW (mg), mean ± SD	1046.02 ± 353.45	920.62 ± 301.47	.01∗
Male (%)	57 of 90 (63)	53 of 101 (52.48)	.085
Normal spontaneous delivery (%)	16 of 58 (28)	37 of 100 (37)	.151
Betamethasone injection (%)	38 of 50 (76)	86 of 100 (86)	.099
RSV bronchiolitis hospitalization (%)	39 of 90 (43)	31 of 101 (31)	.048∗
Length of RSV hospitalization stays (d), mean ± SD	9.82 ± 6.35	6.50 ± 7.57	.035∗
RSV hospitalization and intensive care (%)	9 of 90 (10)	3 of 101 (3)	.044∗
RSV hospitalization and ventilator use (%)	5 of 90 (6)	2 of 101 (2)	.178
Asthma-diagnosed age (mo), mean ± SD	35.80 ± 30.40	37.07 ± 20.74	.740
Long-term medicine prescription for asthma control (%)	68 of 90 (76)	71 of 101 (70)	.258
Allergic rhinitis (%)	57 of 90 (63)	49 of 101 (49)	.028∗
Serum total IgE level (IU/mL), mean ± SD	216.23 ± 343.52	171.40 ± 285.35	.608
Active asthma duration in whole asthmatic children (d), mean ± SD	895.19 ± 932.46	564.93 ± 627.74	.005∗
Active asthma duration in asthmatic children with RSV bronchiolitis hospitalization history (d), mean ± SD	999 ± 998	595 ± 651	.046∗
Active asthma duration in asthmatic children without RSV bronchiolitis hospitalization history (d), mean ± SD	815 ± 880	551 ± 621	.07
Long-term medication prescription days in whole asthmatic children (d), mean ± SD	560.93 ± 892.31	331.76 ± 530.23	.035∗
Long-term medication prescription days in asthmatic children with RSV bronchiolitis hospitalization history (d), mean ± SD	671 ± 948	428 ± 558	.186
Long-term medication prescription days in asthmatic children without RSV bronchiolitis hospitalization history (d), mean ± SD	476 ± 846	289 ± 515	.165

^∗P < .05.